Pain management in Guillain-Barre syndrome: A systematic review

L. Peña; Carlos Moreno Benavides; Ángela María Gutiérrez-Álvarez

doi:10.1016/j.nrl.2014.04.009

Pain management in Guillain-Barre syndrome: A systematic review

Título traducido de la contribución: Manejo del dolor en el síndrome de Guillain-Barré. Revisión sistemática

L. Peña, Carlos Moreno Benavides, Ángela María Gutiérrez-Álvarez

Producción científica: Contribución a una revista › Estudio breve › revisión exhaustiva

9 Citas (Scopus)

Resumen

Introducción
El dolor es un síntoma muy frecuente en los pacientes con síndrome de Guillain-Barré, con una intensidad de moderada a severa en la mayoría de los casos; puede persistir luego de la resolución de la enfermedad.

Objetivo
Identificar la terapia analgésica más apropiada para el manejo del dolor en los pacientes con síndrome de Guillain-Barré.

Material y métodos
Se realizó una búsqueda y selección sistemática de los artículos científicos sobre el tratamiento del dolor en pacientes con síndrome de Guillain-Barré publicados entre enero de 1985 y diciembre de 2012. Se incluyeron solo ensayos clínicos aleatorizados, doble ciego, que evaluaron el efecto de los medicamentos en el tratamiento del dolor en estos pacientes.

Resultados
Cuatro artículos cumplieron los criterios de inclusión. Uno evaluó el uso de gabapentina, otro, el de carbamazepina, otro comparó el uso de gabapentina y carbamazepina, y el último evaluó el uso de metilprednisolona. Tanto carbamazepina como gabapentina fueron útiles en el manejo del dolor. En el estudio que comparó carbamazepina y gabapentina, los pacientes presentaron menor intensidad del dolor con el uso de este último. La metilprednisolona no mostró un efecto positivo en la reducción del dolor. Los datos publicados no permitieron la realización de un metaanálisis.

Conclusiones
No hay evidencia sólida en el momento actual para recomendar una opción terapéutica específica ante este problema. Es necesaria la realización de futuros estudios clínicos que incluyan un mayor número de pacientes, por un tiempo más prolongado, que individualicen los tipos de dolor por pacientes y midan objetivamente la intensidad de este.

Título traducido de la contribución	Manejo del dolor en el síndrome de Guillain-Barré. Revisión sistemática
Idioma original	Inglés estadounidense
Páginas (desde-hasta)	433-438
Número de páginas	6
Publicación	Neurologia
Volumen	30
N.º	7
DOI	https://doi.org/10.1016/j.nrl.2014.04.009 https://doi.org/10.1016/j.nrl.2014.04.009
Estado	Publicada - sep. 1 2015

Áreas temáticas de ASJC Scopus

Neurociencias General

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

Citar esto

@article{36ea3bef19c34705b644fabf83e5bc63,

title = "Pain management in Guillain-Barre syndrome: A systematic review",

abstract = "IntroductionPain is a common symptom in patients with Guillain-Barre syndrome. Intensity is moderate to severe in most cases and pain may persist after resolution of the disease.ObjectiveIdentify the most appropriate analgesic therapy for pain management in patients with Guillain-Barre syndrome.Material and methodsSystematic review and selection of scientific articles on treatment of pain in Guillain-Barre syndrome patients, published between January 1985 and December 2012. We included only randomised, double-blind, controlled trials assessing the effectiveness of drugs for pain management in these patients.ResultsFour articles met the inclusion criteria. One evaluated the use of gabapentin, another evaluated carbamazepine, a third compared gabapentin to carbamazepine, and the last evaluated use of methylprednisolone. Both carbamazepine and gabapentin were useful for pain management. Patients experienced lower-intensity pain with gabapentin treatment in the study comparing that drug to carbamazepine. Methylprednisolone was not shown to be effective for reducing pain. The published data did not permit completion of a meta-analysis.ConclusionsThere is no robust evidence at present that would point to a single treatment option for this disorder. Further clinical studies of larger patient samples and with a longer duration are needed to characterise types of pain for each patient and measure pain intensity in an objective way.",

author = "L. Pe{\~n}a and {Moreno Benavides}, Carlos and Guti{\'e}rrez-{\'A}lvarez, {{\'A}ngela Mar{\'i}a}",

year = "2015",

month = sep,

day = "1",

doi = "10.1016/j.nrl.2014.04.009",

language = "English (US)",

volume = "30",

pages = "433--438",

journal = "Neurologia",

issn = "0213-4853",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Pain management in Guillain-Barre syndrome: A systematic review

AU - Peña, L.

AU - Moreno Benavides, Carlos

AU - Gutiérrez-Álvarez, Ángela María

PY - 2015/9/1

Y1 - 2015/9/1

N2 - IntroductionPain is a common symptom in patients with Guillain-Barre syndrome. Intensity is moderate to severe in most cases and pain may persist after resolution of the disease.ObjectiveIdentify the most appropriate analgesic therapy for pain management in patients with Guillain-Barre syndrome.Material and methodsSystematic review and selection of scientific articles on treatment of pain in Guillain-Barre syndrome patients, published between January 1985 and December 2012. We included only randomised, double-blind, controlled trials assessing the effectiveness of drugs for pain management in these patients.ResultsFour articles met the inclusion criteria. One evaluated the use of gabapentin, another evaluated carbamazepine, a third compared gabapentin to carbamazepine, and the last evaluated use of methylprednisolone. Both carbamazepine and gabapentin were useful for pain management. Patients experienced lower-intensity pain with gabapentin treatment in the study comparing that drug to carbamazepine. Methylprednisolone was not shown to be effective for reducing pain. The published data did not permit completion of a meta-analysis.ConclusionsThere is no robust evidence at present that would point to a single treatment option for this disorder. Further clinical studies of larger patient samples and with a longer duration are needed to characterise types of pain for each patient and measure pain intensity in an objective way.

AB - IntroductionPain is a common symptom in patients with Guillain-Barre syndrome. Intensity is moderate to severe in most cases and pain may persist after resolution of the disease.ObjectiveIdentify the most appropriate analgesic therapy for pain management in patients with Guillain-Barre syndrome.Material and methodsSystematic review and selection of scientific articles on treatment of pain in Guillain-Barre syndrome patients, published between January 1985 and December 2012. We included only randomised, double-blind, controlled trials assessing the effectiveness of drugs for pain management in these patients.ResultsFour articles met the inclusion criteria. One evaluated the use of gabapentin, another evaluated carbamazepine, a third compared gabapentin to carbamazepine, and the last evaluated use of methylprednisolone. Both carbamazepine and gabapentin were useful for pain management. Patients experienced lower-intensity pain with gabapentin treatment in the study comparing that drug to carbamazepine. Methylprednisolone was not shown to be effective for reducing pain. The published data did not permit completion of a meta-analysis.ConclusionsThere is no robust evidence at present that would point to a single treatment option for this disorder. Further clinical studies of larger patient samples and with a longer duration are needed to characterise types of pain for each patient and measure pain intensity in an objective way.

U2 - 10.1016/j.nrl.2014.04.009

DO - 10.1016/j.nrl.2014.04.009

M3 - Short survey

SN - 0213-4853

VL - 30

SP - 433

EP - 438

JO - Neurologia

JF - Neurologia

IS - 7

ER -

Pain management in Guillain-Barre syndrome: A systematic review

Resumen

Áreas temáticas de ASJC Scopus

ODS de las Naciones Unidas

Acceder al documento

Huella

Citar esto